Patel Sandip I
Patel Sandip I, DIR, reported a transaction classified as exercise at Akari Therapeutics Plc involving 6186.000000 shares for an estimated $99965.76. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Oct 14, 2026
- Filing date
- Oct 16, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
AKTX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001493152-26-047456 Pre-Funded Warrant to Purchase ADSs
- Transaction date
- Oct 14, 2026 Filed Oct 16, 2026, 09:20 PM · 2d delay
- Shares
- 6,186 sh $16.16 per share
- Estimated value
- -$99.9k Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
These American Depositary Shares ("ADSs") represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per or…
- F2
These ADSs represent RSUs, with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. This RSU grant was approved by the Board of…
- F3
This award of RSUs was granted in lieu of accrued but unpaid cash retainers payable to non-execute directors in accordance with the Issuer's remuneration policy.
- F4
On August 18, 2026, the Reporting Person was granted an option to purchase 45,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with re…
- F5
On August 18, 2026, the Reporting Person was granted an option to purchase 15,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. Beginning on the date of Sha…
- F6
The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
- F7
The pre-funded warrants remain exercisable until fully exercised.
- F8
On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all ac…
- F9
On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Privat…
- F10
The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16.
0 other transactions
0 recent txs